ATXI - Avenue Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.62
-0.20 (-5.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.82
Open3.74
Bid3.34 x 1100
Ask4.18 x 1400
Day's Range3.42 - 3.90
52 Week Range2.08 - 5.90
Volume56,597
Avg. Volume55,700
Market Cap38.207M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.40
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Trade prices are not sourced from all markets
  • Zacks Small Cap Research2 months ago

    ATXI: Second Quarter 2018 Results

    By John Vandermosten, CFA NASDAQ:ATXI READ THE FULL ATXI RESEARCH REPORT Avenue Therapeutics (NASDAQ:ATXI) provided their press release and their form 10-K including second quarter 2018 financial results ...

  • GlobeNewswire2 months ago

    Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

    Company reported positive Phase 3 data in patients with post-surgical pain following bunionectomy. Initiation of second pivotal Phase 3 trial expected in the second half of 2018. NEW YORK, Aug. 14, 2018-- ...

  • Reuters3 months ago

    Special Report: Biotech incubator taps investors through in-house brokerage

    Last August, National Securities Corp analyst Jonathan Aschoff was bullish on Avenue Therapeutics Inc (ATXI.O), a fledgling biotechnology company with no revenue and one drug in clinical trials. Nearly a year later, Avenue shares are down 36 percent, at about $4. A few months earlier, Aschoff had waxed equally optimistic about another biotech venture, Checkpoint Therapeutics Inc (CKPT.O), with several cancer drugs in various stages of development.

  • Reuters3 months ago

    Special Report: Biotech incubator taps investors through in-house brokerage

    Last August, National Securities Corp analyst Jonathan Aschoff was bullish on Avenue Therapeutics Inc (ATXI.O), a fledgling biotechnology company with no revenue and one drug in clinical trials. Nearly a year later, Avenue shares are down 36 percent, at about $4. A few months earlier, Aschoff had waxed equally optimistic about another biotech venture, Checkpoint Therapeutics Inc (CKPT.O), with several cancer drugs in various stages of development.

  • Zacks Small Cap Research4 months ago

    ATXI: KOL Call with Drs. Singla and Minkowitz on IV Tramadol

    Avenue Therapeutics (ATXI) hosted a moderated discussion on tramadol on June 11 which featured two key opinion leaders (KOLs) in the space. The participants were Dr. Neil Singla and Dr. Harold Minkowitz. Dr. Singla brings a long history developing analgesic medicines to the discussion.

  • ACCESSWIRE5 months ago

    Blog Exposure - Avenue Therapeutics Reported Positive Results from Pivotal Phase-3 Trial of IV Tramadol

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Avenue Therapeutics, Inc. (NASDAQ: ATXI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ATXI as the Company's latest news hit the wire. On May 21, 2018, the Company announced that its first pivotal Phase-3 trial assessing IV tramadol for treatment of patients with moderate to moderately severe postoperative pain following bunionectomy surgery achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 48 hours (SPID48) compared to placebo. Active-Investors.com is currently working on the research report for Taro Pharmaceutical Industries Ltd (NYSE: TARO), which also belongs to the Healthcare sector as the Company Avenue Therapeutics.

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Fibrocell Science Inc (NASDAQ: FCSC ) stock gained ...

  • Zacks Small Cap Research5 months ago

    ATXI: 1Q:18 Update Confirms Timeline

    By John Vandermosten, CFA NASDAQ:ATXI Avenue Therapeutics (NASDAQ:ATXI) circulated a press release and their form 10-K with their first quarter 2018 financial results on May 3rd. Total expenses for the ...

  • Zacks Small Cap Research6 months ago

    ATXI: No Pain? We See a Gain; Developing Tramadol

    Avenue Therapeutics (ATXI) is developing IV tramadol for postoperative pain. Avenue has licensed a patented administration of IV tramadol that is able to limit side effects and provide a solution for moderate to severe pain which avoids many of the risks of opioids and non-steroidal anti-inflammatory drugs (NSAIDs). The drug also allows for transition to step down therapy with oral tramadol, which mirrors the pharmacokinetic, side effect profile and pain control of the IV form.